Enochian BioSciences Announces the Appointment of Executive Vice President of Research and Development with 25 years of Industry Experience

Rhea-AI Summary

Enochian BioSciences (NASDAQ: ENOB) has appointed Dr. François Binette as Executive Vice President for Research and Development. With over 25 years of experience in Advanced Therapy and Regenerative Medicine, Dr. Binette previously served as Senior VP of Product Development at Lineage Cell Therapeutics, leading significant allogenic cell therapy initiatives. His expertise is expected to enhance Enochian's pipeline and facilitate progress towards regulatory and clinical milestones, as highlighted by CEO Dr. Mark Dybul.

Positive

• Appointment of Dr. François Binette brings over 25 years of experience in Advanced Therapy and Regenerative Medicine.
• Dr. Binette's leadership is expected to drive Enochian's development pipeline towards key regulatory and clinical milestones.

Negative

• None.

LOS ANGELES, April 20, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences (NASDAQ: ENOB). Enochian BioSciences Inc., a company focused on gene-modified cellular and immunotherapies in infectious diseases and cancer, today is announcing the appointment of Dr. François Binette, Ph.D. as Executive Vice President for Research and Development. Dr. Binette brings over 25 years of Advanced Therapy and Regenerative Medicine product development expertise, most recently as Senior VP of Product Development at Lineage Cell Therapeutics where he led multiple innovative allogenic cell therapy programs from discovery to clinical stages and contributed to one of the largest non-cancer cell therapy corporate partnership deals with Genentech worth over $650 million in upfront and milestone payments. He previously held positions at Johnson and Johnson, where he led several innovative regenerative medicine combination product development initiatives from discovery to approved clinical trials in the US and Europe, and at Medtronics, developing biologics, active devices, and combination products.

“Enochian is very excited that Dr. Binette will be leading Research and Development. His broad expertise in Big Pharma and BioTech in driving pipeline and product development for innovative therapies to ensure swift transition, comes at a perfect time for the trajectory of the Company and for the development of our pipeline toward key regulatory and clinical milestones,” said Dr. Mark Dybul, Enochian’s CEO.

“My entire professional career has focused on advancing new therapeutic modalities to provide definitive curative therapies to diseases with little to no treatment options. I was struck with the breakthrough innovation paving the way toward potential cures for many diseases that Enochian is spearheading, and feel privilege to be part of it,” Francois said.

FAQ

What is the significance of Dr. François Binette's appointment at Enochian BioSciences?

Dr. François Binette's appointment is significant as he brings extensive experience in Advanced Therapy and Regenerative Medicine, which may enhance Enochian's research and development efforts.

How might Dr. Binette's background impact Enochian BioSciences?

Dr. Binette's background in leading product development at major biotech firms could accelerate Enochian's pipeline advancements and help achieve clinical milestones.

What are Dr. Binette's previous roles before joining Enochian BioSciences?

Before joining Enochian, Dr. Binette was Senior VP at Lineage Cell Therapeutics and held positions at Johnson and Johnson and Medtronics, focusing on innovative therapy development.

What is Enochian BioSciences' focus area?

Enochian BioSciences focuses on gene-modified cellular and immunotherapies in the treatment of infectious diseases and cancer.